Stock of the Day

Today's Trend

Altimmune, Inc. (NASDAQ: ALT) is likely moving on a mix of encouraging clinical and financial updates, partly offset by a broker price-target cut.

• Altimmune reported first-quarter 2026 results that beat loss expectations, with EPS of ($0.18) versus the consensus ($0.25). Even though revenue was nil, the narrower-than-expected loss suggests better cost control as the company advances its pipeline. Altimmune Announces First Quarter 2026 Financial Results and Business Update
• The company said it now expects its cash runway to extend into 2029, supported by $535 million in cash, cash equivalents and short-term investments as of April 30. That reduces near-term financing risk and gives Altimmune more time to advance pemvidutide. Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
• Altimmune said it plans to start the PERFORMA Phase 3 MASH trial in 2H 2026, reinforcing the development timeline for pemvidutide in a key market. The company also highlighted upcoming EASL presentations featuring additional IMPACT Phase 2b data, which could keep investor attention on the program. Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

• Altimmune’s Q1 2026 earnings call and transcript provide additional detail on management’s plans, but do not appear to add a major new catalyst beyond the earnings release and pipeline update. Altimmune (ALT) Q1 2026 Earnings Transcript
• Altimmune’s 48-week IMPACT Phase 2b MASH data will be showcased at EASL 2026, including a “Best of EASL 2026” selection. This is supportive of the scientific story, but investors are still waiting for larger Phase 3 confirmation. Altimmune, Inc. Announces Presentation of IMPACT Phase 2b Study Results at EASL Congress 2026

• Citizens JMP lowered its price target on Altimmune from $14 to $11, which may have pressured sentiment despite keeping a market outperform rating. The cut suggests more cautious expectations around the stock’s near-term upside. Benzinga report on Citizens JMP price target cut

Bottom line: ALT is getting support from better-than-expected quarterly losses, a long cash runway, and progress toward Phase 3 in MASH, but the analyst price-target reduction is a headwind.